Evidence map›Paper›PMID 35008362›Full record

ArticleCancers2021

Combined Fluorescence and Optoacoustic Imaging for Monitoring Treatments against CT26 Tumors with Photoactivatable Liposomes.

Ilya Turchin, Shazia Bano, Mikhail Kirillin, Anna Orlova, Valeriya Perekatova, Vladimir Plekhanov, Ekaterina Sergeeva, Daria Kurakina, Aleksandr Khilov, Alexey Kurnikov and 7 more

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.0field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 4 institutions in 2 countries.

Ilya TurchinInstitute of Applied Physics RAS, 46 Ulyanov St., 603950 Nizhny Novgorod, Russia.ORCID 0000-0002-8471-7361
Shazia BanoWellman Center for Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.ORCID 0000-0002-8870-3805
Mikhail KirillinInstitute of Applied Physics RAS, 46 Ulyanov St., 603950 Nizhny Novgorod, Russia.ORCID 0000-0002-6804-6369
Anna OrlovaInstitute of Applied Physics RAS, 46 Ulyanov St., 603950 Nizhny Novgorod, Russia.ORCID 0000-0002-9844-4683
Valeriya PerekatovaInstitute of Applied Physics RAS, 46 Ulyanov St., 603950 Nizhny Novgorod, Russia.
Vladimir PlekhanovInstitute of Applied Physics RAS, 46 Ulyanov St., 603950 Nizhny Novgorod, Russia.ORCID 0000-0003-0233-2052
Ekaterina SergeevaInstitute of Applied Physics RAS, 46 Ulyanov St., 603950 Nizhny Novgorod, Russia.
Daria KurakinaInstitute of Applied Physics RAS, 46 Ulyanov St., 603950 Nizhny Novgorod, Russia.ORCID 0000-0002-4436-2535
Aleksandr KhilovInstitute of Applied Physics RAS, 46 Ulyanov St., 603950 Nizhny Novgorod, Russia.ORCID 0000-0002-2075-9634
Alexey KurnikovInstitute of Applied Physics RAS, 46 Ulyanov St., 603950 Nizhny Novgorod, Russia.
Pavel SubochevInstitute of Applied Physics RAS, 46 Ulyanov St., 603950 Nizhny Novgorod, Russia.
Marina ShirmanovaInstitute of Experimental Oncology and Biomedical Technologies, Privolzhsky Research Medical University, 10/1 Minin and Pozharsky Sq., 603005 Nizhny Novgorod, Russia.
Anastasiya KomarovaInstitute of Experimental Oncology and Biomedical Technologies, Privolzhsky Research Medical University, 10/1 Minin and Pozharsky Sq., 603005 Nizhny Novgorod, Russia.
Diana YuzhakovaInstitute of Experimental Oncology and Biomedical Technologies, Privolzhsky Research Medical University, 10/1 Minin and Pozharsky Sq., 603005 Nizhny Novgorod, Russia.
Alena GavrinaInstitute of Experimental Oncology and Biomedical Technologies, Privolzhsky Research Medical University, 10/1 Minin and Pozharsky Sq., 603005 Nizhny Novgorod, Russia.
Srivalleesha MallidiWellman Center for Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.ORCID 0000-0003-1547-1764
Tayyaba HasanWellman Center for Photomedicine, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.ORCID 0000-0003-0871-6057
Institute of Applied Physics · RUPrivolzhsky Research Medical University · RUHarvard University · USTufts University · US

Funding

Optical imaging guided resection and photodynamic therapy of glioma with targeted photoactivable agentsR21CA220143 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI HASAN, TAYYABA · 2017 to 2019
$390k
NIH HHS R21CA220143Russian Foundation for Basic Research 17-54-33043Russian Science Foundation 19-75-10055
6 · The paper itself

Abstract

The newly developed multimodal imaging system combining raster-scan optoacoustic (OA) microscopy and fluorescence (FL) wide-field imaging was used for characterizing the tumor vascular structure with 38/50 μm axial/transverse resolution and assessment of photosensitizer fluorescence kinetics during treatment with novel theranostic agents. A multifunctional photoactivatable multi-inhibitor liposomal (PMILs) nano platform was engineered here, containing a clinically approved photosensitizer, Benzoporphyrin derivative (BPD) in the bilayer, and topoisomerase I inhibitor, Irinotecan (IRI) in its inner core, for a synergetic therapeutic impact. The optimized PMIL was anionic, with the hydrodynamic diameter of 131.6 ± 2.1 nm and polydispersity index (PDI) of 0.05 ± 0.01, and the zeta potential between -14.9 ± 1.04 to -16.9 ± 0.92 mV. In the in vivo studies on BALB/c mice with CT26 tumors were performed to evaluate PMILs' therapeutic efficacy. PMILs demonstrated the best inhibitory effect of 97% on tumor growth compared to the treatment with BPD-PC containing liposomes (PALs), 81%, or IRI containing liposomes (L-[IRI]) alone, 50%. This confirms the release of IRI within the tumor cells upon PMILs triggering by NIR light, which is additionally illustrated by FL monitoring demonstrating enhancement of drug accumulation in tumor initiated by PDT in 24 h after the treatment. OA monitoring revealed the largest alterations of the tumor vascular structure in the PMILs treated mice as compared to BPD-PC or IRI treated mice. The results were further corroborated with histological data that also showed a 5-fold higher percentage of hemorrhages in PMIL treated mice compared to the control groups. Overall, these results suggest that multifunctional PMILs simultaneously delivering PDT and chemotherapy agents along with OA and FL multi-modal imaging offers an efficient and personalized image-guided platform to improve cancer treatment outcomes.

Indexed as

fluorescence imagingmulti-inhibitor liposomesnanoconstructsoptoacoustic imagingphotodynamic therapytumor vasculature

Identifiers

PMID35008362
PMCPMC8750546
OpenAlexW4206788521

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.